- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07272655
Hemiarcada vs. Arcada Total com FET para Dissecação Aórtica Tipo A
Um Estudo Prospectivo, Randomizado, Duplamente Cego, de Não-Inferioridade Comparando a Substituição da Aorta Ascendente/Hemi-arco Versus Substituição Total do Arco com Tronco de Elefante Congelado em Doentes com Hematoma Intramural da Aorta Tipo A
This is a prospective, randomized, non-inferiority clinical trial designed to compare the efficacy and safety of two surgical strategies for acute type A aortic intramural hematoma (TAIMH): (1) ascending aorta replacement or ascending aorta plus hemiarch replacement (AAR/AAR+HAR), and (2) ascending aorta replacement with total arch replacement and frozen elephant trunk implantation (AAR+TAR+FET). Patients will be enrolled based on CTA confirmation of a completely thrombosed false lumen in the ascending aorta and aortic arch. Eligible participants will be randomized in a 1:1 ratio to either group. The primary endpoint is the rate of reintervention on the aortic arch or descending aorta from 6 to 12 months after surgery. Secondary endpoints include circulatory arrest time, aortic cross-clamp time, major adverse cardiovascular events, other perioperative complications, and total hospitalization cost. A total of 400 participants will be enrolled.
Visão geral do estudo
Status
Condições
Descrição detalhada
This is a prospective, randomized, controlled, non-inferiority study comparing two surgical strategies for acute type A aortic intramural hematoma (TAIMH). Patients with acute TAIMH will be screened and enrolled based on CTA confirmation of a completely thrombosed false lumen in the ascending aorta and aortic arch. Participants will be randomly assigned in a 1:1 ratio to receive either AAR/AAR+HAR or AAR+TAR+FET, with 200 participants in each group. Postoperative CTA will be performed before discharge, and follow-up CTA will be performed at 6 to 12 months after surgery.
The surgical procedure will be performed through a median sternotomy or upper partial sternotomy. Cardiopulmonary bypass will be established through right axillary/femoral arterial and bicaval venous cannulation, or femoral arteriovenous cannulation and superior vena cava cannulation. Left ventricular venting will be achieved via the right superior pulmonary vein. Antegrade HTK or cold blood cardioplegia will be administered under direct vision and repeated every 30 minutes. During circulatory arrest, bilateral selective antegrade cerebral perfusion will be provided via the right axillary artery and left common carotid artery.
The primary endpoint is the rate of reintervention on the aortic arch or descending aorta from 6 to 12 months after surgery. Secondary endpoints include circulatory arrest time, aortic cross-clamp time, major adverse cardiovascular events, other perioperative complications, and total hospitalization cost. The trial is designed to test whether the less extensive AAR/AAR+HAR strategy is non-inferior to AAR+TAR+FET with respect to the primary endpoint, while potentially offering advantages in operative burden, perioperative safety, and hospitalization cost.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: kexiang liu, MD,Ph.D.
- Número de telefone: 17390920328
- E-mail: kxliu64@hotmail.com
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Age ≥ 18 years and ≤ 80 years.
- Diagnosis of type A aortic intramural hematoma (TAIMH).
- Ability to understand the study procedure and provide written informed consent.
Exclusion Criteria:
- Preoperative CTA shows an open or partially thrombosed (mixed) false lumen in the ascending aorta or arch.
- Primary tear located on the greater curvature of the aortic arch, necessitating total arch replacement.
- Planned concomitant major cardiac surgery (e.g., CABG, valve replacement, atrial fibrillation ablation).
- Previous history of aortic arch or distal aortic surgery.
- Severe peripheral vascular disease or cerebrovascular anatomy abnormality.
- Active systemic infection, malignancy, severe hepatic or renal dysfunction, or other major comorbidities with life expectancy < 1 year or deemed unfit for complex cardiovascular surgery.
- Pregnancy or lactation.
- Severe psychiatric or cognitive disorders affecting compliance or follow-up.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Dobro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: AAR/AAR+HAR Group
Participants randomized to this group will undergo ascending aorta replacement alone or ascending aorta plus hemiarch replacement (AAR/AAR+HAR), according to the operative strategy. This procedure involves replacing the ascending aorta with or without replacement of the proximal aortic arch while preserving the distal arch and supra-aortic vessels. |
This procedure involves ascending aorta replacement alone or ascending aorta plus hemiarch replacement, according to the operative strategy. The ascending aorta is replaced with or without replacement of the proximal aortic arch, while the distal arch and supra-aortic vessels are preserved.
Outros nomes:
|
|
Comparador Ativo: AAR+TAR+FET Group
Participants randomized to this group will undergo ascending aorta replacement with total arch replacement and frozen elephant trunk implantation (AAR+TAR+FET). This procedure involves replacement of the entire aortic arch combined with frozen elephant trunk repair of the proximal descending aorta. |
This procedure involves ascending aorta replacement with total arch replacement and frozen elephant trunk implantation. The entire aortic arch is replaced, and a frozen elephant trunk is implanted into the proximal descending aorta.
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Rate of reintervention on the aortic arch or descending aorta
Prazo: 6 to 12 months after surgery
|
The proportion of patients requiring any secondary surgical or endovascular procedure involving the aortic arch or descending aorta during follow-up after the index operation. |
6 to 12 months after surgery
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Aortic Cross-Clamp Time
Prazo: Intraoperative
|
Duration (minutes) of aortic cross-clamping during surgery. |
Intraoperative
|
|
Circulatory Arrest Time
Prazo: Intraoperative
|
Duration (minutes) of total circulatory arrest. |
Intraoperative
|
|
Major Adverse Cardiovascular Events (MACE)
Prazo: Through 30 days after surgery
|
Incidence of major adverse cardiovascular events during the perioperative period. The exact components should follow the study protocol and statistical analysis plan. |
Through 30 days after surgery
|
|
Other perioperative complications
Prazo: Through 30 days after surgery
|
Incidence of perioperative complications during the perioperative period, including but not limited to neurological events, renal dysfunction, infection, bleeding, and cardiac failure. |
Through 30 days after surgery
|
|
Total hospitalization cost
Prazo: Through hospital discharge
|
The total direct medical cost incurred during the index hospitalization, including surgery, intensive care, ward stay, medications, blood products, imaging, laboratory tests, procedures, and other treatment-related in-hospital expenses. |
Through hospital discharge
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: kexiang Liu, Ph.D., Department of Cardiovascular Surgery, The Second Hospital of Jilin University
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- JDEY-TAIMH
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
De-identified individual participant data (IPD) that underlie the results reported in the published article will be shared. This includes baseline demographic data, clinical characteristics, operative details, and all primary and secondary outcome measures collected during the study. Additionally, the study protocol, statistical analysis plan (SAP), and clinical study report (CSR) will be made available to provide context for the data.
Prazo de Compartilhamento de IPD
Beginning 6 months after the publication of the primary results and for a period of 5 years.
Critérios de acesso de compartilhamento IPD
Researchers with a methodologically sound proposal, approved by an independent review committee. Data requestors will be required to sign a data access agreement.
Tipo de informação de suporte de compartilhamento de IPD
- PROTOCOLO DE ESTUDO
- SEIVA
- CIF
- CSR
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .